Journal of Medicinal Chemistry p. 5623 - 5642 (2018)
Update date:2022-08-15
Topics:
Wang, Feng
Jeon, Kyu Ok
Salovich, James M.
Macdonald, Jonathan D.
Alvarado, Joseph
Gogliotti, Rocco D.
Phan, Jason
Olejniczak, Edward T.
Sun, Qi
Wang, Shidong
Camper, Demarco
Yuh, Joannes P.
Shaw, J. Grace
Sai, Jiqing
Rossanese, Olivia W.
Tansey, William P.
Stauffer, Shaun R.
Fesik, Stephen W.
WDR5 is a chromatin-regulatory scaffold protein overexpressed in various cancers and a potential epigenetic drug target for the treatment of mixed-lineage leukemia. Here, we describe the discovery of potent and selective WDR5-WIN-site inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified several chemically distinct hit series that bind to the WIN site within WDR5. Members of a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole fragment class were expanded using a structure-based design approach to arrive at lead compounds with dissociation constants <10 nM and micromolar cellular activity against an AML-leukemia cell line. These compounds represent starting points for the discovery of clinically useful WDR5 inhibitors for the treatment of cancer.
View MoreChengdu King-tiger Pharm-chem. Tech. Co., Ltd
Contact:028-85317716
Address:Tianfu Life Science Park, No. 88 South Keyuan Road, Gaoxin District, Chengdu City, Sichuan Province, PRC.
Contact:86-571-61063068
Address:LINAN
website:http://www.tcfinechem.com/
Contact:18681346930
Address:baifu town,whou district
Contact:13813902930 025-52714267
Address:20 Fengji Road, Yuhua Economic Development Zone, Nanjing, Jiangsu, P. R. China
website:http://www.synchemie.com/
Contact:+86-574-87642758
Address:Room 901, Yinyi Bund Building, 132 Renmin Road
Doi:10.1007/BF00763697
(1986)Doi:10.1080/00397919608003762
(1996)Doi:10.1016/j.tet.2012.09.087
(2012)Doi:10.1021/acscatal.8b00923
(2018)Doi:10.1248/cpb.34.1950
(1986)Doi:10.1016/j.tet.2008.08.010
(2008)